BOSTON, Feb. 6, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Emmanuel Dulac, PharmD, Ph.D., and Kim Cobleigh Drapkin, CPA, have been appointed to the Company's Board of Directors.
Dr. Dulac joined Alnylam Pharmaceuticals in August 2016 as Chief Commercial Officer to establish the company's global commercial organization. He has over twenty years of international biotechnology and pharmaceutical industry expertise, launching and marketing multiple drugs, including cystic fibrosis products. Ms. Drapkin is the Chief Financial Officer at Jounce Therapeutics, Inc. She has over two decades of financial leadership experience working with private and publicly traded biotechnology and pharmaceutical companies, establishing financial infrastructure, raising capital and leading strategic financial planning.
"Emmanuel and Kim are seasoned life sciences leaders and we are fortunate to welcome them to PTI's board of directors," said Meenu Chhabra, President and Chief Executive Officer of Proteostasis. "Collectively, Emmanuel's clinical development and commercial expertise, particularly in cystic fibrosis, and Kim's experience working for a broad range of growing biotech companies, will provide PTI valuable insight as we approach multiple key data readouts of our proprietary combinations and add-on CF therapies."
Prior to Alnylam, Dr. Dulac led the Rare Disease Business Unit at Shire and held several leadership roles of increasing responsibility at Novartis, Abbott and Sanofi. Notably, he led the clinical trials, global regulatory approvals and global launch of TOBI® podhaler for cystic fibrosis patients. During his career, Dr. Dulac has built successful sales, patient services, marketing and market access organizations. He has launched five brands and led two blockbuster drugs globally. He graduated from the University of Paris XI with a Doctorate in Pharmacology (PharmD, Ph.D.) and completed an MBA from the ESSEC School in Paris.
"PTI is an emerging leader in cystic fibrosis, a disease area in which I have significant clinical, commercial background and personal connections. I'm excited to join the board and contribute to the development of these promising new treatment options for CF patients," commented Dr. Dulac.
Prior to her role at Jounce, Ms. Drapkin owned a financial consulting firm, where she served as Interim CFO for numerous early stage biotechnology companies, including Avila Therapeutics, Blueprint Medicines, Eleven Biotherapeutics, NinePoint Medical, and Voyager Therapeutics. Prior, Ms. Drapkin served as CFO of EPIX Pharmaceuticals for four years. For the preceding ten years, she served at Millennium Pharmaceuticals, Inc. as Director of Finance, with leadership responsibility for financial reporting, technical accounting, internal audit and Sarbanes Oxley initial implementation and compliance. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. She earned her B.S. from Babson College and is a Certified Public Accountant.
"I am pleased to be joining the PTI board of directors and I look forward to sharing my financial leadership experience with the other board members and the management team to support the strategic growth of the Company," commented Ms. Drapkin.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit www.proteostasis.com.
To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this release include, without limitation, statements regarding the potential of our proprietary combination therapies for the treatment of CF, the potential benefit to patients of our proprietary combination therapies, expected timing of the data from our clinical studies and our expectations regarding our new board members. Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the uncertainties inherent in the execution and completion of clinical trials, in the timing of availability of trial data, in the results of the clinical trials, in the actions of regulatory agencies, in the commercialization and acceptance of new therapies, and those set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Proteostasis Therapeutics, Inc.